Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JCR Pharmaceuticals CoTSE:4552 +0.57%46 EV-to-EBIT is 45.95 as of Sep. 07, 2026, which is 41% above its 10-year median of 32.63. GuruFocus rates TSE:4552 with a GF Score™ of 46/100 and a GF Value™ of 円787.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 681 Drug Manufacturers companies, JCR Pharmaceuticals Co ranks worse than 81.79% on this metric.
JCR Pharmaceuticals Co (TSE:4552) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
JCR Pharmaceuticals Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円109,594 Mil.
JCR Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,367 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JCR Pharmaceuticals Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where JCR Pharmaceuticals Co's EV-to-EBIT falls into.
JCR Pharmaceuticals Co's current Enterprise Value is 円108,755 Mil.
JCR Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,367 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JCR Pharmaceuticals Co (TSE:4552) has a EV-to-EBIT of 45.95 as of Sep. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on JCR Pharmaceuticals Co and its competitors. This is 41% above median its historical median of 32.63. According to the industry distribution chart, JCR Pharmaceuticals Co ranks #557 out of 681 companies in the Drug Manufacturers industry, placing it in the top 81.8%.
Is JCR Pharmaceuticals Co's EV-to-EBIT too high?
JCR Pharmaceuticals Co's current EV-to-EBIT of 45.95 is 41% above median its 10-year median of 32.63. The Drug Manufacturers industry median EV-to-EBIT is 15.89. JCR Pharmaceuticals Co's value of 45.95 is 189.2% above this industry median. Based on the distribution chart, JCR Pharmaceuticals Co ranks #557 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, JCR Pharmaceuticals Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, JCR Pharmaceuticals Co ranks #557 out of 681 companies for EV-to-EBIT. This places JCR Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-EBIT is 15.89. JCR Pharmaceuticals Co's value of 45.95 is 189.2% above this benchmark. While the company's 10-year median is 32.63 vs. the industry median of 15.89, JCR Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.89, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JCR Pharmaceuticals Co's current EV-to-EBIT of 45.95 is 189.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on JCR Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JCR Pharmaceuticals Co's current EV-to-EBIT is 45.95, which is 41% above median its own 10-year median of 32.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (TSE:4552) is currently considered Possible Value Trap. The stock's GF Value™ is 円787.71, compared to a current price of 円528.00 — trading 33% below its estimated fair value. The current EV-to-EBIT is 45.95, which is 41% above median its 10-year median of 32.63 and 189.2% above the Drug Manufacturers industry median of 15.89. JCR Pharmaceuticals Co's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For JCR Pharmaceuticals Co (TSE:4552), the current EV-to-EBIT is 45.95 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JCR Pharmaceuticals Co (TSE:4552) Overvalued in 2026?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued.
The current stock price of 円528.00 is trading 33% below its estimated GF Value™ of 円787.71.
GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for TSE:4552:
EV-to-EBIT: 45.95 (41% above median its 10-year median of 32.63)
GF Value™: 円787.71 vs. price of 円528.00 (33% below fair value)
Industry Position: 189.2% above the Drug Manufacturers median (#557 of 681)
No single metric tells the full story. See the TSE:4552 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
46GF Score
Get the complete analysis for TSE:4552
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4552 has been successfully added to your 
